Company Data
Geron Corporation
Ticker
GERN
Current Price
$3.5 -6.17%
Market Cap
$1.9B
Price Target
Refer to Report
Volume
10.4M
52wk Range
$1.64 - $4.05
Overview
Geron Corp is a clinical stage biopharmaceutical company. Its focus is the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imelstat is expected to directly obstruct malignant-cell proliferation. The company has an exclusive collaboration and license agreement with Janssen Biotech to develop and commercialize imetelstat worldwide for oncology and other human therapeutic uses.